The global hypogonadism treatment market is estimated to register a CAGR of 5% during the forecast period, during the forecast period and registers a revenue valued at US$ 3.62 Bn in 2022, and is expected to cross US$ 5.90 Bn by 2032.
| Attributes | Details |
|---|---|
| Hypogonadism Treatment Market Size (2022) | US$ 3.62 Billion |
| Hypogonadism Treatment Market Size (2032) | US$ 5.90 Billion |
| Hypogonadism Treatment Market CAGR | 5% |
Doctors have recommended making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and consistently low serum T concentrations. They have further recommended measuring ‘fasting morning’ total T concentrations using an accurate and reliable assay as the initial diagnostic test. In addition, there are several testosterone formulations available currently, and numerous additional formulations are being developed. This is expected to surge the global hypogonadism treatment market growth.
Furthermore, there are few alternative therapies that are used lesser for managing male hypogonadism. This may prove advantageous for some patient groups. According to statistics, 'hypogonadism’s future therapy may be in developing selective androgen receptor modulators which aid the advantages of androgens. They also minimize unwanted, ill effects. This can be a growth opportunity for market players.
It is said that early detection in young boys can aid in problems such as delayed puberty. Early diagnosis and treatment in men offer better protection against osteoporosis and other related conditions. This can be done by conducting a physical exam by the patient’s healthcare provider, who also notes whether the sexual development, such as the pubic hair, muscle mass, and size of testes, is consistent with age. This evidently is estimated to propel the adoption of hypogonadism treatment.
Apart from gel formulations, testosterone replacement therapy can also be done through injections where testosterone cypionate (depo-testosterone) and testosterone enanthate are given in a muscle or under the skin. The symptoms might waver between doses depending on the frequency of injections. Other popular ways hypogonadism treatment is done are patch, gum and cheek, nasal, and implantable pellets. All these factors are anticipated to surge product demand and expand the global hypogonadism treatment market size.
Hypogonadism refers to diminished activity of reproductive organs producing little or no hormones. In males, hypogonadism refers to the decrease in either of the functions of the testes i.e. sperm production and testosterone production. It affects the men of all ages. While in females, hypogonadism refers to decreased activity of ovaries leading to reduction in the levels of estrogen and progesterone.
Hypogonadism may lead to infertility, fatigue, muscle loss, depression, poor concentration and memory and reduced libido. Hypogonadism is classified into two categories namely, primary and secondary hypogonadism, based on the causative factors. Primary hypogonadism (hypergonadotropic hypogonadism) refers to abnormality in the gonads or testicles responsible for low androgen and estrogen levels.
Whereas, in secondary hypogonadism (hypogonadotropic hypogonadism), the problem lies in the brain. The hypothalamus and pituitary gland in the brain, which control the gonads, aren’t working properly.
Key providers of hypogonadism treatment have been involved in successful product launches that are generating opportunities for testosterone production complications. For instance, a key market player announced that their recently launched clear, odorless testosterone gel formulation, “AndroGel 1.62%,” which restores testosterone levels in hypogonadal men, has been approved by the U.S. Food and Drug Administration (FDA). The key player claims that this product has half the volume of gel at the starting dose compared to its prequel, AndroGel 1%. Both the gel formulations are prescription medications used to treat adult males with low or no testosterone. These factors are estimated to drive the demand for hypogonadism treatment.
In the United States, nearly 14 Mn men may have low testosterone levels. Moreover, the Endocrine Society noted that the normal range for testosterone is 300-1,000 ng/dL and has developed guidelines for the diagnosis and treatment of hypogonadism. This particular gel has been used by physicians and patients for more than a decade and is a revered innovation to treat the condition. Other testosterone solutions have also been launched by key players who have entered into an exclusive worldwide license agreement for their potential commercialization, which supports global hypogonadism treatment market growth. However, the drug applications of some of these solutions are still under regulatory review by the U.S. Food and Drug Administration (FDA).
The market players are focused on developing a growing portfolio of pharmaceutical products by applying the latest research from their own worldwide laboratories and forming collaborations with eminent scientific organizations. Furthermore, they strive to provide answers, through medicines and information, to the families of patients for some of the world’s most urgent medical needs. Hence, this leads to the high adoption of hypogonadism treatment. They claim that their research and development (R&D) pipeline includes 81 clinical-stage projects, 31 of which are in phase 3 or have been submitted to regulatory authorities for approval. These projects are made possible by people who volunteer to participate in a clinical trial, some of which are new molecular entities while others are existing products with potential new indications. These factors are likely to expand the global hypogonadism treatment market size.
Lack of sex hormones can lead to other complaints like increased risk of heart disease and osteoporosis, due to thinning of bones. This has led to the growth of hypogonadism treatment market. Moreover, the market has presence of patented brands with huge sales. Hypogonadism incidence will rise with increasing age and increasing incidence of obesity and rheumatoid arthritis.
In addition, changing lifestyle habits associated with smoking and increasing stress levels also lead to reduced androgen and estrogen levels. These are some of the driving force for hypogonadism treatment market. However, the entry of generics would lead to sales erosion of the top brands in the market, thus restraining the hypogonadism treatment market to grow to certain extent.
The treatment modality for hypogonadism mainly incudes testosterone replacement through exogenous administration. However, for spermatogenesis, gonadotropins are preferred as testosterone is identified to be less effective. In females, estrogen and progesterone hormones are replaced by exogenous administration.
Therefore, the market is analyzed based on hormonal replacement therapy as testosterone, gonadotropins, estrogen and progesterone. Pre-menopausal women can benefit from estrogen that comes in pill or patch form. Treatment for males and females is similar if the hypogonadism is due to a tumor on the pituitary gland. Treatment may include radiation, medication or surgery to shrink or remove the tumor.
Region wise, the global hypogonadism treatment marketis classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is the largest market for hypogonadism treatment with the presence of high prevalence of the disease. However, the industry will be experiencing higher demand from the developing regions such as Latin America, Asia-Pacific, Middle-East and Africa.
Some of the key players in the hypogonadism treatment market include Abbott Laboratories, Inc., Bayer AG, Eli Lilly and Company, Merck Serono, Merck & Co., Inc., Actavis, Inc. and Sanofi S.A.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The hypogonadism treatment market can be segmented based on product type, distribution channel and geography.
The market is likely to register a CAGR of 5% through 2032.
The market is currently valued at US$ 3.62 Bn in 2022.
The market is likely to grow to a valuation of US$ 5.90 Bn by 2032.
North America is likely to be a leading market during the forecast period.
Explore Similar Insights
Hypogonadism Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
